OncoMatch

OncoMatch/Clinical Trials/NCT07282587

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Is NCT07282587 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ONC206 and ONC206: Dose 1 for advanced pheochromocytoma and paraganglioma.

Phase 2RecruitingJazz PharmaceuticalsNCT07282587Data as of May 2026

Treatment: ONC206 · ONC206: Dose 1 · ONC206: Dose 2This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: ONC206 or dordaviprone (ONC201) (ONC206, dordaviprone, ONC201)

Has previous exposure to ONC206 or dordaviprone (ONC201) from any source.

Lab requirements

Blood counts

Has laboratory test results meeting the following parameters within 14 days before the first dose of study treatment

Kidney function

Has laboratory test results meeting the following parameters within 14 days before the first dose of study treatment

Liver function

Has laboratory test results meeting the following parameters within 14 days before the first dose of study treatment

Cardiac function

No active cardiac disease/condition including: QTc >480 msec, NYHA III-IV CHF, unstable angina, acute MI, or recent arterial bypass/PTCA within 6 months

Has laboratory test results meeting the following parameters within 14 days before the first dose of study treatment; Has active cardiac disease/condition including any of the following: Corrected QT interval (QTc) >480 msec, history of documented congestive heart failure (NYHA III-IV), unstable angina, acute myocardial infarction, or arterial bypass or percutaneous transluminal coronary angioplasty within 6 months

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UCLA · Los Angeles, California
  • Stanford · Palo Alto, California
  • U of Colorado · Aurora, Colorado
  • U of Michigan · Ann Arbor, Michigan
  • Mayo-Rochester · Rochester, Minnesota

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify